Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology's Kidney Week 2025 [Yahoo! Finance]
Humacyte, Inc. (HUMA)
Company Research
Source: Yahoo! Finance
fistula in high-need subgroups with historically poor outcomes with AV fistula procedures – – The significantly longer duration of ATEV use in these high-need patients could greatly reduce reliance on catheters for dialysis access, a major cause of complications, morbidity and cost in dialysis patients – DURHAM, N.C., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced the presentation of positive two-year results from the V007 Phase 3 clinical trial of the acellular tissue engineered vessel (ATEV) in arteriovenous (AV) access for hemodialysis patients at the American Society of Nephrology's (ASN) Kidney Week 2025 , the premier nephrology meeting, in Houston. In the V007 Phase 3 trial, the ATEV was observed to have superior duration of use over 24 months as compared to autogenous fistula in female, obese and diabetic patient
Show less
Read more
Impact Snapshot
Event Time:
HUMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HUMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HUMA alerts
High impacting Humacyte, Inc. news events
Weekly update
A roundup of the hottest topics
HUMA
News
- Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Humacyte (HUMA) Q3 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $6.00 price target on the stock.MarketBeat
- Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.MarketBeat
HUMA
Earnings
- 11/12/25 - Beat
HUMA
Sec Filings
- 11/26/25 - Form 8-K
- 11/17/25 - Form 4
- 11/17/25 - Form 4
- HUMA's page on the SEC website